Evidence map›Paper›PMID 42798949›Full record

ArticleFrontiers in immunology2026

Correction: Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1.

Ines Zettl, Isabella Ellinger, Mohammed Zghaebi, Sarah Jance, Vanessa Izewski, Anja Drescher, Heimo Breiteneder, Manuel Röck, Martin Tollinger, Julia Eckl-Dorna and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ines ZettlInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Isabella EllingerInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Mohammed ZghaebiVienna Airway Lab, Department of Otolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
Sarah JanceInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Vanessa IzewskiInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Anja DrescherCytiva Europe GmbH, Freiburg, Germany.
Heimo BreitenederInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Manuel RöckDepartment of Organic Chemistry, University of Innsbruck, Innsbruck, Austria.
Martin TollingerDepartment of Organic Chemistry, University of Innsbruck, Innsbruck, Austria.
Julia Eckl-DornaVienna Airway Lab, Department of Otolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
Sergei V TillibInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
Sabine FlickerInstitute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2026.1864741.].

Indexed as

birch pollen allergybispecific nanobodyICAM-1respiratory epitheliumtopical treatment

Identifiers

PMID42798949
PMCPMC13613330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.